Anti-GRM5 polyclonal antibody,[Alexa Fluor® 555]

Attention deficit hyperactivity disorder (ADHD) is a common childhood behavioral condition which affects 2-10% of school age children worldwide. Although the underlying molecular mechanism for the disorder is poorly understood, familial, twin and adoption studies suggest a strong genetic component. Here we provide a state-of-the-art review of the molecular genetics of ADHD incorporating evidence from candidate gene and linkage designs, as well as genome-wide association (GWA) studies of common single-nucleotide polymorphisms (SNPs) and rare copy number variations (CNVs). Bioinformatic methods such as functional enrichment analysis and protein-protein network analysis are used to highlight biological processes of likely relevance to the aetiology of ADHD. Candidate gene associations of minor effect size have been replicated across a number of genes including SLC6A3, DRD5, DRD4, SLC6A4, LPHN3, SNAP-25, HTR1B, NOS1 and GIT1. Although case-control SNP-GWAS have had limited success in identifying common genetic variants for ADHD that surpass critical significance thresholds, quantitative trait designs suggest promising associations with Cadherin13 and glucose-fructose oxidoreductase domain 1 genes. Further, CNVs mapped to glutamate receptor genes (GRM1, GRM5, GRM7 and GRM8) have been implicated in the aetiology of the disorder and overlap with bioinformatic predictions based on ADHD GWAS SNP data regarding enriched pathways. Although increases in sample size across multi-center cohorts will likely yield important new results, we advocate that this must occur in parallel with a shift away from categorical case-control approaches that view ADHD as a unitary construct, towards dimensional approaches that incorporate endophenotypes and statistical classification methods.

Background: Oral cancer represents the third most prevalent form of malignancy in developing countries and the eight most common form of cancer in developed countries. Alcohol and tobacco users are most affected by oral cancers and 90% of them are OSCC in adult males. In some provinces in Iran such as Sistan and Baluchestan, its prevalence is higher compared to other provinces. One of the primary neurotransmitter in the central nervous system is systemic glutamate, which is a major excitatory neurotransmitter. Glutamate signaling has been involved in various non-neuronal cancer processes. The aim of this research was to highlight the association between DNA methylation of the glutamate receptor genes and their expression pattern in pathogenesis of OSCC. Materials and methods: Genomic DNA was isolated from 83 OSCC paraffin-embedded tissues (mean age: 59.67 +/- 16.08) and 80 normal samples (mean age: 50.15 +/- 16.69). Promoter methylation status of glutamate receptors including GRM5, GRM2 and GRIA3 genes were carried out by Methylation Specific PCR technique (MSP). We also investigated the mRNA expression levels of these genes in 15 paraffin-embedded patients and healthy samples using real-time PCR techniques. Result: DNA methylation analysis showed statistically significant differences in the cases in comparison with healthy controls. Our data showed that the promoters of GRM2 and GRIA3 were methylated in the cases. For GRM2 (MM: OR = 0.32; 95% CI = 0.02-3.90; p-value = .37; MU: OR = 8.0; 95% CI = 1.37-47.34; p-value = .02) and GRIA3 (MM: OR = 47.19; 95% CI = 4.61-483.0; p-value = .001; MU: OR = 1.45; 95% CI = 0.35-5.89; p-value = .6). However, methylation of GRM5 promoter was not statistically different in the cases and healthy controls, GRM5 (MM: OR = 0.9; 95% CI = 0.14-5.71; p-value = 0.9; MU: OR = 1.83; 95% CI = 0.33-10.09; p-value = .4). In addition, the evaluation of mRNA expression levels of GRM2, GRIA3 and GRM5 were remarkably different in patients and healthy controls (p < .0001). Summarily, the aim of this study was to assess the methylation and expression pattern of GluR genes and the risk of OSCC. We are of the presupposition that methylation and expression statuses of the chosen genes, GRM5, GRM2 and GRIA3 might be significant biomarkers for OSCC.